OKYO

OKYO Pharma Limited

NasdaqCM · USD

Analyze chart

$1.57+$0.02 +1.29%At close 4:00 PM ET · Sep 4, 2026

$1.57+$0.00+0.00%

OKYO Community →

Key statistics

Market cap$82.39M

P/E ratio-2.38

EPS-0.24

Beta0.00

Day high$1.60

Day low$1.52

52-week high$3.20

52-week low$1.34

Volume32.94K

Avg volume100.54K

Dividend yield—

About OKYO Pharma Limited

HealthcareBiotechnologyNasdaqCM

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Website: okyopharma.com
Employees: 5
Headquarters: London, United Kingdom

What's your take on OKYO?

Be the first to share your outlook and start the conversation with other investors in the OKYO community.

Share your take